NeuroScientific Biopharmaceuticals Limited announced that as a result of the change in strategy of the company's R&D pathway, two new directors have joined the Board to assist with a strategic review of the company's assets and future direction. Mr. Clarke Barlow and Mr. Chris Ntoumenopoulos will both join the Board, effective 17 November 2023. Mr. Chris Ntoumenopoulos is the Managing Director of Twenty 1 Corporate, an Australian advisory firm.

With over 20 years in financial markets, he has a strong background in raising capital and offering corporate advisory services. His experience also extends to directorial roles, having served on the boards of ASX listed companies for over 7 years. Chris was a foundational director of ResApp Health Ltd., later acquired by Pfizer, and Race Oncology (RAC.ASX).

Presently, Chris is a non-executive director at Medibio (MEB.ASX). Mr. Clarke Barlow is a Financial Adviser with 22 years' experience in the Financial Services Industry in Australia and the United Kingdom (UK). Since 2007, Clarke has provided corporate advisory services for ASX listed companies across a variety of industries, with a focus on growth opportunities, providing them with advice on business models & strategy, structuring of pre-IPO and IPO fund raisings, reverse takeovers, capital raisings, M&A, investor relations and capital markets advice.

Mr. Barlow currently serves as a Non-Executive Director of ASX listed biotechnology company Exopharm Limited (ASX: EX1) and is a Founder and Director of AMG Acquisition Corp, a publicly listed company on the Toronto Venture Exchange. He holds a Bachelor of Commerce degree from the University of Western Australia, has level 2 ASX derivatives accreditation, and is a member of the Australian Institute of Company Directors (AICD). As a result of this change in strategy and direction, Dr. Linda Friedland has chosen not to stand for election at the upcoming Annual General Meeting, and therefore steps down from the Board effective 17 November 2023.